SCIEX and Children's Medical Research Institute Join Forces to Advance the Promise of Precision Medicine

SCIEX industrialized proteomics solutions, using SWATH^® Acquisition-based workflows and powered by the OneOmics™ Project, will enable large scale proteome studies to advance cancer research

February 03, 2016

Framingham, MA and Sydney, Australia — SCIEX, a global leader in life science analytical technologies, today announced their alliance with Children’s Medical Research Institute (CMRI) to equip The Australian Cancer Research Foundation International Centre for the Proteome of Cancer (ProCan™) facility with the solutions and tools required for the advancement of their large-scale proteomic profiling studies. These studies will profile thousands of tumour samples per year, enable discoveries around the causes of cancer, provide guidance of cancer treatment options, and work to produce standard operating procedures for other facilities around the world. ProCan will be established with $10 million in seed money from The Australian Cancer Research Foundation to purchase the SCIEX equipment.

The agreement provides ProCan with the high sample throughput required for the industrialisation of proteomics via a large suite of SCIEX TripleTOF® 6600 mass spectrometers and NanoLC 400 HPLCs, to create one of the world's largest scale implementations of the SCIEX next-generation proteomics solution, featuring SWATH® Acquisition and OneOmics cloud computing. Additionally ProCan will benefit from SCIEX’s exclusive collaborators, Pressure Biosciences and Beckman Coulter, using Pressure Cycling Technology and liquid handling workstations for increased protein quantitation and reproducibility.

Dr. Christie Hunter (SCIEX Director of OMICs Applications) visits the ProCan facility to meet with CMRI Chief Scientists and Executives and begin the implementation of the SCIEX Industrialized Proteomics solution. From left to right; Dr. Christie Hunter, Prof. Roger Reddel (Director of CMRI and Head of Cancer research Unit), Chris Hodgkins (Market Development Manager, SCIEX Oceania), Prof. Phil Robinson (Head of Cell Signaling Unit and co-developer of ProCan) and Valentina Valova (Manager of Biomedical Proteomics Facility and ProCan, CMRI).

"Large-scale proteomics studies have great potential to improve our understanding of cancer at the molecular level, but are subject to significant variability caused in sample preparation, data acquisition and interpretation," said Chris Radloff, Global Vice President and General Manager of the LC-MS Business at SCIEX. "Through our partnership with CMRI and the designation of ProCan as a SCIEX Centre of Innovation in Precision Medicine, SCIEX solutions reduce that variability and enable higher sample throughput, which will help to accelerate cancer research and precision medicine at large."

"Collaborating with SCIEX will enable ProCan to accomplish our vision of one day, delivering a proteomics report on every clinician's desk," said Professor Phil Robinson, Head of the Cell Signalling Unit at CMRI and co-developer of ProCan with Professor Roger Reddel, Head of CMRI's Cancer Research Unit. "The unique industrial proteomics platform we are developing will unlock the potential of our discoveries and empower us to perform the translation research needed to rapidly identify the cause of each individual cancer, advancing scientific discovery and allowing a more accurate prediction of the best cancer treatments for individual patients."

SCIEX will designate ProCan as a "SCIEX Centre of Innovation in Precision Medicine" and will include SCIEX scientists working with researchers from CMRI to develop and trial new omics workflows in a real-world setting. SCIEX and CMRI will discuss further details about the centre at the 21st Annual Lorne Proteomics Symposium 2016."

Scientists from SCIEX will be presenting Multi-Omics workshops and poster presentations at the 21st Annual Lorne Proteomics Symposium 2016, held February 4th through the 7th at Mantra Lorne, Lorne Victoria.

Learn more about SCIEX Proteomics Solutions and CMRI

About SCIEX

SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.

With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com

SCIEX social: @SCIEXnews, LinkedIn, and Facebook.

Contact Information
Lulu VanZandt
Program Manager, Brand, Public Relations and Social Media, SCIEX
lulu.vanzandt@sciex.com
+1 (508) 383-7163
M: +1 (508) 782-9484

AB Sciex is operating as SCIEX.
© 2018 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used under license.

For research use only. Not for use in diagnostic procedures.

Request information